Novel Systemic Anticancer Therapy and Healthcare Utilization at the End of Life: A Retrospective Cohort Study.

Cancer Med · 2024 · PMC11626481 · PMID 39651705

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

While previous studies have demonstrated an increasing trend in HCRU at the end of life for patients with advanced cancer [ 21 , 27 , 28 ], much of these data predate the novel SACT era dominated by targeted and immunotherapies.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.